Background
Materials and methods
Patients
Immunohistochemistry
Statistical methods and analysis
Results
Patient characteristics and clinicopathological data
Parameter | Category | Overall | TGIF expression | p-value | ||||
---|---|---|---|---|---|---|---|---|
0–2 | 3–12 | |||||||
N | % | N | % | N | % | |||
All patients | 1197 | 475 | 39.7% | 722 | 60.3% | |||
Age (years) | < 40 | 185 | 15.5% | 73 | 15.4% | 112 | 15.5% | 0.756 |
40–50 | 489 | 40.9 | 196 | 41.3% | 293 | 40.6% | ||
51–65 | 496 | 41.4% | 56 | 48.7% | 440 | 40.7% | ||
> 65 | 27 | 2.3% | 8 | 1.7% | 19 | 2.6% | ||
Tumor stage (pT) | pT1 | 394 | 33.0% | 134 | 28.4% | 260 | 36.1% | 0.015 |
pT2 | 665 | 55.7% | 286 | 60.6% | 379 | 52.6% | ||
pT3/4 | 134 | 11.2% | 52 | 11.0% | 82 | 11.4% | ||
total | 1193 | 472 | 721 | |||||
missing | 4 | |||||||
Lymph node status (pN) | pN1 | 493 | 41.2% | 181 | 38.1% | 312 | 43.2% | 0.114 |
pN2 | 398 | 33.2% | 159 | 33.5% | 239 | 33.1% | ||
pN3 | 306 | 25.6% | 135 | 28.4% | 171 | 23.7% | ||
Tumor grading (G) | G1 | 39 | 3.3% | 13 | 2.7% | 26 | 3.6% | < 0.001 |
G2 | 588 | 49.2% | 196 | 41.4% | 392 | 54.3% | ||
G3 | 569 | 47.6% | 265 | 55.9% | 304 | 42.1% | ||
missing | 1 | |||||||
Histological type | ductal | 930 | 77.7% | 389 | 81.9% | 541 | 74.9% | 0.009 |
lobular | 136 | 11.4% | 39 | 8.2% | 97 | 13.4% | ||
others | 131 | 10.9% | 47 | 9.9% | 84 | 11.6% | ||
HER2 | positive | 248 | 22.0% | 89 | 20.4% | 159 | 23.0% | 0.303 |
negative | 880 | 78.0% | 348 | 79.6% | 532 | 77.0% | ||
missing | 69 | |||||||
ER | positive | 886 | 74.0% | 322 | 67.8% | 564 | 78.1% | < 0.001 |
negative | 311 | 26.0% | 153 | 32.2% | 158 | 21.9% | ||
PR | positive | 819 | 68.4% | 285 | 60.0% | 534 | 74.0% | < 0.001 |
negative | 378 | 31.6% | 190 | 40.0% | 188 | 26.0% | ||
Treatment in mITTset | iddEPC | 597 | 49.9% | 232 | 48.8% | 365 | 50.6% | 0.595 |
ddEC-PwX | 600 | 50.1% | 243 | 51.2% | 357 | 49.4% | ||
Ibandronate treatment | with Ibandronate | 781 | 65.2% | 307 | 64.6% | 474 | 65.7% | 0.756 |
without Ibandronate | 416 | 34.8% | 168 | 35.4% | 248 | 34.3% |
TGIF expression in tumor tissue
Elevated TGIF expression correlates with longer DFS and OS
Analysis | Parameter | DFS | OS | ||||
---|---|---|---|---|---|---|---|
HRa (95%CI) | Log-rank p-value | Bivariate interaction p-value | HRa (95%CI) | Log-rank p-value | Bivariate interaction p-value | ||
Overall | |||||||
TGIF moderate/strong | 0.75 (0.59–0.95) | 0.019 | – | 0.69 (0.51–0.94) | 0.018 | – | |
Subgroups | |||||||
iddEPC | moderate/strong TGIF | 0.70 (0.50–0.98) | 0.036 | 0.575 | 0.69 (0.45–1.07) | 0.095 | 0.978 |
ddEC-PwX | moderate/strong TGIF | 0.81 (0.58–1.14) | 0.228 | 0.69 (0.45–1.08) | 0.105 | ||
Ibandronate treatment | moderate/strong TGIF | 0.79 (0.59–1.07) | 0.131 | 0.620 | 0.72 (0.49–1.06) | 0.094 | 0.729 |
without Ibandronate treatment | moderate/strong TGIF | 0.68 (0.46–1.01) | 0.057 | 0.64 (0.38–1.07) | 0.087 | ||
ER-negative | moderate/strong TGIF | 1.03 (0.67–1.58) | 0.893 | 0.130 | 1.02 (0.60–1.75) | 0.933 | 0.107 |
ER-positive | moderate/strong TGIF | 0.68 (0.51–0.91) | 0.009 | 0.60 (0.41–0.88) | 0.008 | ||
HER2-negative | moderate/strong TGIF | 0.67 (0.50–0.88) | 0.004 | 0.034 | 0.57 (0.40–0.82) | 0.002 | 0.015 |
HER2-positive | moderate/strong TGIF | 1.27 (0.75–2.18) | 0.375 | 1.79 (0.80–4.00) | 0.151 | ||
TNBC | moderate/strong TGIF | 1.00 (0.57–1.75) | 0.995 | 0.427 | 1.05 (0.56–1.96) | 0.876 | 0.291 |
non-TNBC | moderate/strong TGIF | 0.76 (0.58–1.00) | 0.049 | 0.70 (0.48–1.01) | 0.055 |